iRegene

Wuhan, China · Founded 2017 · Privately Held (backing)

Developer of chemically-derived allogeneic cell therapies aims to provide first-in-class treatments for major degenerative diseases. iRegene is based in Wuhan, China and was founded in 2017. Its last reported valuation was $569 million in Apr 2025. It has raised $393 million.

Last reported valuation
$568.6M
Oct 2026
Priced at
—
Total raised
$392.8M
Last round
—
No prints on record

No secondary trades in iRegene shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of iRegene with a free account
  • ·The complete investor list: 14 names
  • ·Watch iRegene: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where iRegene prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of iRegene stock.